Long COVID, Brief Dream: Phase II Flop Sparks End of PureTech’s Bid to Treat Coronavirus Complications

PureTech Health’s long COVID trial has come up short. The drug candidate failed to help patients with the condition walk farther, prompting the company to drop plans for further studies in the indication.